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Background: Anesthesia induction with desflurane is troublesome because of the frequent sympathetic hyperactivity 
during desflurane administration. We thought that a low concentration of desflurane combined with a target-
controlled infusion (TCI) of remifentanil would eliminate the desflurane-related complications and provide 
hemodynamic stability during desflurane induction. An up-and-down study was planned to find the target effect-site 
concentration of remifentanil to block the hemodynamic response to endotracheal intubation, the highest level of 
stimulus, during anesthesia induction with administering desflurane at 1 MAC.
Methods: Remifentanil TCI was initiated before desflurane administration. When the preset target was achieved, 
spontaneous inhalation of desflurane 1 MAC was performed until the patients became unconscious. Laryngoscopic 
tracheal intubation was facilitated with rocuronium injection. The starting concentration of remifentanil and the 
test space were 5 and 1 ng/ml, respectively. The criteria for up-and-down was a 20% increase of the mean arterial 
pressure or heart rate after intubation. The median effective concentration (EC50) of remifentanil was calculated from 
6 independent pairs. The complications related with remifentanil and desflurane were assessed during the study.
Results: We studied 20 patients using 2-5 ng/ml of the effect-site concentrations of remifentanil. The EC50 of 
remifentanil was 3.7 ng/ml. Loss of consciousness was achieved at 125 ± 22 s after desflurane inhalation and this was 
irrespective of the combined remifentanil concentrations. Any remifentanil-related complication was not observed. 
Transient cough was seen in one patient who received 2 ng/ml of remifentanil.
Conclusions: We demonstrated that uncomplicated induction with desflurane was possible by the use of target-
controlled remifentanil. The EC50 of remifentanil to block the hemodynamic response to tracheal intubation was 3.7 
ng/ml during inhalational induction with 1 MAC desflurane. (Korean J Anesthesiol 2011; 60: 12-18)
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Introduction
    A high alveolar concentration of volatile anesthetic often 
depresses the pre-intubation blood pressure to clinically 
unacceptable levels in order to achieve normal blood pressure 
after tracheal intubation [1]. In case of desflurane, a rapid 
increase of the alveolar concentration greater than 1 minimum 
alveolar concentration (MAC), which was required to blunt the 
hemodynamic response to tracheal intubation, was frequently 
related with tachycardia and hypertension [2,3]. Suppression 
of the sympathetic responses to desflurane itself as well as to 
tracheal intubation required cumbersome pharmacologic 
interventions during the brief period of anesthesia induction [4].
    Recent studies have indicated that low concentrations of 
volatile anesthetics were frequently combined with a large dose 
of opioid to ensure unawareness and hemodynamic stability 
during surgery [5,6]. The concept of balanced anesthesia may 
be adopted for anesthesia induction with desflurane [7]. We 
thought that an inspiratory desflurane concentration of 1 
MAC would be sufficient to induce unawareness, resulting in 
less desflurane-related complications than that with higher 
concentrations of desflurane. Combining a target-controlled 
infusion (TCI) of remifentanil would suppress the signs of 
desflurane-related stimulation and provide anesthetic synergy 
with desflurane, hemodynamic stability and convenient control 
to maintain stable effect-site concentrations.
    In the current study, our primary end-point was to determine 
a median effective effect-site concentration of remifentanil 
to block the hemodynamic response to tracheal intubation 
during the administration of an inspiratory desflurane 
concentration of 1 MAC, and we did this by performing an up-
and-down study (a dose-finding study to investigate a dose 
with a certain probability of effectiveness, usually 50%, in 
sequentially allocated patients). In addition, the desflurane and 
remifentanil-related complications were assessed during the 
study.
Materials and Methods
    After obtaining the approval of our institutional review board 
and written informed consent from the patients, the American 
Society of Anesthesiologists I-II patients (aged 18-60 years) 
who were scheduled for elective general surgeries such as breast 
and thyroid surgeries and laparoscopic cholecystectomy were 
consecutively enrolled into the study. The patients who were 
anticipated to have difficulty with laryngoscopy, those with 
a recent history of or those with ongoing cardiac, pulmonary 
or renal diseases and those currently taking analgesic or 
antihypertensive medications were excluded from the study. No 
patients received premedication before the study.
    The patient arrived in the operating room with an 18 G 
intravenous catheter on the forearm, and standard monitoring 
was applied to the patient, including electrocardiography, 
noninvasive blood pressure and pulse oxymetry (Solaris 
8000M Patient Monitor, GE Medical Systems, Milwaukee, WI). 
A bispectral index (BIS) monitor (BIS-XP monitor, Aspect 
Medical Systems Inc., Natick, MA) was applied to the patient. 
Remifentanil (Ultiva
TM inj., 1mg vial, GlaxoSmithKline, Belgium) 
was diluted into 50 ml of normal saline (20 μg/ml solution) and 
this was put into a commercial TCI device (Orchestra
Ⓡ Base 
Primea, Fresenius Vial, France). A microvolume extension tube 
was connected to the intravenous catheter via a 3-way stopcock. 
The TCI device was operated in the effect-site control mode 
using the pharmacokinetic model of Minto and colleagues [8]. 
The end-tidal concentrations of desflurane and carbon dioxide 
were measured with a multi-gas analyzer integrated into the 
anesthetic ventilator (Primus, Dräger Medical AG & Co. KGaA, 
Germany).
    The starting target effect-site concentration of remifentanil 
was empirically set at 5 ng/ml. Using this starting concentration, 
our preliminary study showed that the incremental or 
decremental change in the target concentration was as large 
as 20% of the initial concentration. We finally determined that 
the starting and step-size concentrations were 5 and 1 ng/
ml, respectively. The response of each patient determined the 
target concentration of remifentanil administered to the next 
patient. A successful response was defined as the increase of 
heart rate (HR) or mean arterial pressure (MAP) at 1 min after 
intubation that did not exceed 20% of the value just before 
laryngoscopic intubation. If the HR or MAP exceeded 20% of the 
pre-intubation value, then it was defined as a failed response. If 
a successful response was noted, then the target concentration 
of remifentanil was lowered by 1 ng/ml for the next patient, 
and in case of a failure response, the target concentration of 
remifentanil was increased by 1 ng/ml. Before entering the test, 
rescue regimens to treat the adverse effects of remifentanil or 
desflurane were prepared as follows: atropine for bradycardia, 
ephedrine for hypotension, esmolol for tachycardia and both 
propofol and succinylcholine for chest rigidity and airway 
spasm.
    The schematic of this study is outlined in Fig. 1. The patients 
received remifentanil via the effect-site TCI under oxygen 
supplement through a fitted facial mask. Remifentanil-
associated major complications such as chest wall rigidity, 
bradycardia and hypotension were assessed until the predicted 
target effect-site concentration of remifentanil reached the 
preset level. Desflurane administration followed through the 
fitted facial mask along with 8 L/min of 100% oxygen. With 
100% oxygen, the dial of the desflurane vaporizer was set at a 
1 MAC concentration that was calculated using Mapleson’s 14 www.ekja.org
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equation (MACage = MAC40 × 10
-0.00269(age-40), where MACage is 
the age-corrected MAC value and MAC40 is 1 MAC for a 40 
year old patient. For example, 1 MAC of desflurane was 6.6 
vol% for a 40-year-old patient and 5.8 vol% for a 60-year-old 
patient [9]. Spontaneous mouth breathing was encouraged 
until patient failed to respond to verbal commands to breathe 
deeply and open their eyes. During this period, the signs of 
desflurane-associated airway irritation (cough, excessive 
salivation, laryngospasm and bronchospasm) and the signs of 
sympathetic stimulation (tachycardia and hypertension) were 
assessed. When the patient lost consciousness, which was again 
confirmed with an Observer’s Assessment of Alertness/Sedation 
(OAA/S) score of 1 [10], rocuronium 0.9 mg/kg was injected to 
facilitate tracheal intubation. Controlled manual ventilation 
continued for an additional 5 min to the supposed equilibriums 
of both remifentanil and desflurane. Tracheal intubation was 
then performed using direct laryngoscopy. After tracheal 
intubation was secured, the lungs were mechanically ventilated 
using an individually adjusted ventilator setting (tidal volume = 
8 ml/kg, frequency = 10/min) at 2 L/min of fresh gas flow with 
50% oxygen in air along with a lowered target concentration of 
remifentanil set at 2 ng/ml during the next 5 min.
    The measured variables during the study included the HR, 
MAP and SpO2, the end tidal concentrations of carbon dioxide 
(EtCO2) and desflurane (EtDES) and the BIS values. These 
variables were measured at different time points such as the time 
before anesthesia induction (baseline), the time when the target 
effect-site concentration was reached (tCe), the time of loss of 
consciousness (LOC), just before laryngoscopic intubation (BI) 
and every 1 min during the first 5 min after intubation (I + 1, I 
+ 2, I + 3, I + 4 and I + 5).
    On the first postoperative day, the patients were questioned 
about whether they had an explicit recall of memory about the 
events during induction.
Statistical analysis
    When a success response was followed by a failure response, 
such a change in response was termed a “crossover” . A crossover 
showed a midpoint concentration between consecutive 
success and failure response concentrations. This study was 
terminated after six crossovers had occurred. The six crossovers 
were averaged to determine a median effective effect-site 
concentration (EC50) of remifentanil [11] (Fig. 2). The involved 
patients were divided into 2 groups such as success and failure 
groups according to the post-intubation responses. The group 
characteristics were compared using unpaired t-tests and 
Fisher’s exact test. The complication rates were compared 
with the chi-square test. For the measured variables, a t-test 
was performed for comparison of two means, and repeated 
measures analysis of variance with the Student-Newman-
Keuls post hoc test was used for comparing several means. A 
correlation test was done to reveal the relationship between the 
remifentanil concentrations and the time to LOC. The data is 
presented as means ± SDs. SPSS (version 12, SPSS Inc., Chicago, 
IL, USA) was used for the statistical analysis. P values < 0.05 
were considered significant.
Results
    A total of 22 patients entered the study. Two patients were 
dropped during the study because of unpredicted difficult 
laryngoscopy (the 5th patient) and severe bradycardia (HR = 35 
bpm) during tracheal intubation (the 13th patient); anesthesia 
induction was uneventful after 3 attempts of direct laryngoscopy 
Fig. 1. Schematic representation of 
des  flurane-remifentanil anesthesia 
induction.
Fig. 2. Up-and-down sequence. A successful response was defined 
as the increase of the heart rate or mean arterial pressure at 1 min 
after intubation that did not exceed 20% of the value just before 
laryngoscopic intubation. If the heart rate or mean arterial pressure 
exceeded 20% of the pre-intubation value, then it was defined as a 
failed response. A change between consecutive successful and failed 
responses is a “crossover” with a midpoint concentration between 
the successful and failed concentrations. Six crossovers were 
averaged to determine a median effective effect-site concentration of 
remifentanil.15 www.ekja.org
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and an atropine injection, respectively. However, these two 
patients were excluded from the analysis, and the same target 
concentrations were tried again for the next patients. Finally, 
20 patients were included in the analysis (Table 1). From 6 
crossovers, the median effective effect-site concentration of remi-
fentanil to blunt the hemodynamic responses to laryngoscopic 
tracheal intubation was calculated as 3.7 ng/ml (Fig. 2).
    The success and failure groups included 10 patients each. 
The groups’ characteristics were comparable between the two 
groups except for the target remifentanil concentrations (Table 1). 
The only difference of the measured variables between the two 
groups was that the increases of HR and MAP after tracheal 
intubation were significantly less in the success group, as 
indicated by the group definition.
    Until the remifentanil concentration reached the preset level, 
all the patients were fully awake (OAA/S = 5). All the patients 
maintained self-respiration and followed verbal commands to 
breathe deeply during desflurane inhalation. The EtCO2 was 
maintained in the lower normal range during remifentanil 
pretreatment and desflurane inhalation (34 ± 5 and 32 ± 5 
mmHg, respectively). The exhaled concentration of desflurane 
was 0.7 ± 0.1 MAC at the time of LOC and 0.7-0.8 MAC 
thereafter. The BIS values were not different between baseline 
(96 ± 2) and the time when the target remifentanil concentration 
was achieved (92 ± 5). The BIS dropped slightly at the time of 
LOC (85 ± 4), yet a significant reduction was noted at the time 
of intubation (60 ± 14). The BIS was maintained between 46 and 
53 during the next 5 min (Fig. 3). The mean time to LOC after 
desflurane inhalation was 125 ± 22 s. The time to LOC was not 
correlated with the combined remifentanil concentrations (R = 
-0.208, P = 0.379).
    Any complications related with remifentanil TCI were not 
observed except for mild dizziness in three patients. A sign 
of airway irritation was noted in one patient, in whom mild 
and transient cough occurred during desflurane inhalation 
when 2 ng/ml of remifentanil was infused. Neither tachycardia 
nor hypertension occurred during desflurane inhalation. 
No hypoxic episode was noted during the study. None of the 
patients complained of discomfort during desflurane inhalation 
and none were associated with explicit recall of memory.
Discussion
    In the current study, we demonstrated that inhalation of 
desflurane combined with remifentanil TCI resulted in uncom-
plicated anesthesia induction. Our up-and-down study showed 
that 3.7 ng/ml was the EC50 of the remifentanil effect-site concen-
tration to attenuate the hemodynamic response to tracheal 
intu  bation when combined with 1 MAC desflurane.
    Two frequent problems related with the use of desflurane are 
sympathetic stimulation and signs of airway irritation during 
anesthesia induction. Sympathetic hyperactivity in the form 
of hypertension and tachycardia was noted during increasing 
the desflurane concentration from 1.0 to 1.5 MAC in healthy 
young volunteers [2]. Increasing the alveolar concentration 
of desflurane from 0.55 MAC to 1.66 MAC caused doubling 
of the blood pressure and heart rate, and 10-fold increase of 
the plasma catecholamine level [3]. Anesthesia induction 
with desflurane was troublesome because of sudden rises of 
the HR and blood pressure during desflurane administration, 
and the overlapped tachycardia or hypertension after tracheal 
intubation could be detrimental to susceptible patients. Signs 
of airway irritation such as coughing, laryngospasm, breath-
holding, copious secretions and excitatory movements also 
occurred when high concentrations of desflurane were 
administered [12]. The high pungency of desflurane mades 
volatile induction of anesthesia with desflurane unacceptable. 
However, these two complications were minimal or not evident 
when desflurane was administered at concentrations less than 
1 MAC [13,14]. Thus, we postulated that the desflurane-related 
complications would be eliminated by using as low as 1 MAC of 
desflurane. The inspiratory concentration rather than expiratory 
Table 1. Group Characteristics
Group Total Success Failure
Number of patients
Gender (M/F)
Age (yr)
Height (cm)
Weight (kg)
Time to unawareness (sec)*
Target remifentanil concentration (ng/ml)
Complications
20
  2/18
41 ± 9
161 ± 7
61 ± 11
125 ± 22
3.9 ± 0.9
Cough (1)
10
0/10
42 ± 8
162 ± 5
63 ± 10
121 ± 17
4.4 ± 0.7
None
10
2/8
40 ± 10
160 ± 9
59 ± 11
129 ± 26
3.4 ± 0.7
†
Cough (1)
If an increase of the heart rate or mean arterial pressure was confined to 20% of the pre-intubation value following laryngoscopic intubation, 
then the patient wasincluded in the success group. If the heart rate or mean arterial pressure exceeded 20% of the pre-intubation value, then 
the patient was included in the failure group. *Elapsed time from the start of desflurane inhalation to patient’s unawareness, 
†P = 0.014 vs. the 
success group.16 www.ekja.org
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concentration of desflurane would be set to 1 MAC because the 
airway receptors were the afferent site of sympathetic activation 
independent of the changes in the systemic anesthetic 
concentrations [15]. However, anesthesia induction with a low 
concentration of desflurane still requires an anesthetic adjuvant 
such as opioid in order to remove the residual desflurane 
complications and to get analgesic support during tracheal 
intubation.
    Co-administration of fentanyl successfully attenuated the 
desflurane-related complications during desflurane anesthesia 
induction. Previous clinical studies have demonstrated that 
1 and 1.5 μg/kg of intravenous fentanyl were effective to treat 
airway irritability and sympathetic hyperactivity following 
desflurane administration, respectively [4,16]. Larger doses 
such as 4 and 5-10 μg/kg of intravenous fentanyl blocked 
the hemodynamic response to tracheal intubation [17,18]. 
However, bolus fentanyl seems less practical because repetitive 
injections of different doses are required along with the time 
course of anesthesia induction. In the current study, we 
adopted the TCI of remifentanil to deliver a stable analgesic 
concentration on the basis of an integrated pharmacokinetic 
model and a computer-controlled infusion pump. Moreover, 
we targeted the highest level of stimulus such as an intubation 
response because desflurane-related complications are 
less intense responses than the hemodynamic response to 
tracheal intubation according to the above-mentioned dose-
Fig. 3. Sequential comparison of the changes in the heart rate, mean arterial pressure, the minimum alveolar concentration and the bispectral 
index between the success and failure groups during the study. If an increase of the heart rate or mean arterial pressure was confined to 
20% of the pre-intubation value following laryngoscopic intubation, then the patient was included in the success group. If the heart rate 
or mean arterial pressure exceeded 20% of the pre-intubation value, then the patient was included in the failure group. Baseline: the time 
before anesthesia induction, tCe: the time when the targeted effect-site concentration was reached, LOC: the time when the patient became 
unconscious, BI: just before laryngoscopic intubation, I + 1, I + 2, I + 3, I + 4 and I + 5: every 1 min during the first 5 min after intubation. *P 
< 0.05 vs. the baseline value, 
†P < 0.05 vs. the BI value, 
‡P < 0.05 vs. the failure group.17 www.ekja.org
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response relationships. The safety of a pretreatment infusion at 
considerably high concentration was previously demonstrated 
by Lee and colleagues [19].
    Using a low concentration of desflurane, one of our concerns 
was whether inhaling 1 MAC desflurane was sufficient to 
induce unawareness. The MAC-awake, which insures unawa-
reness in 50% of the patients receiving the agent, was 0.36 MAC 
for desflurane [20]. Anesthetic concentrations 1.5-2 times the 
MAC-awake were related with suppression of recall of memory 
and preclusion of awareness in 100% of patients [21]. Nel and 
colleagues [22] determined the time to achieve an expired 
concentration to an inspired concentration ratio of 0.7 was 
2 min during the initial administration of desflurane using 
high flow fresh gas. Our result showed that twice the MAC-
awake (0.7 MAC) end-tidal desflurane was achieved in 2 min 
by inhaling 1 MAC of desflurane. At this concentration, all the 
patients lost their consciousness and none of them complained 
of recall of memory postoperatively. However, the shortening of 
the LOC time in the patients who received more remifentanil, 
according to the opioid-volatile synergy on hypnosis [23], 
was not revealed in this study. This might be due to the weak 
influence of the combined opioid on hypnosis with a ceiling 
effect at lower concentrations [17,24]. The small sample size 
of this up-and-down study might also have been responsible 
for this. Nonetheless, this balanced induction technique may 
be acceptable from a viewpoint of the rapidity. The time to 
LOC was not prolonged compared with the induction times 
using the TCI of propofol (100 s) or inhalational induction 
with sevoflurane (41-178 s) or the previous studies that tried 
volatile induction with desflurane-nitrous oxide at higher MAC 
equivalents (2-4 min) [16,25-27].
    This study might be criticized for several points. First, per-
forming volatile induction with desflurane may be criticized 
when patients have intravenous routes. There is consensus for 
the use of volatile induction for cases with failed intravenous 
catheterization, and especially in children. In the current 
study, volatile induction was considered from the beginning 
to eliminate the effect of confounding factors such as using 
an intravenous hypnotic agent. However, volatile induction 
balanced with opioid assured stable vital signs since an 
abrupt increase of anesthetic concentrations by either an 
overpressurized volatile agent or a bolus of intravenous 
anesthetic was avoided [28]. Eliminating the pain of propofol 
injections was also advantageous. We do not claim that this 
method has priority over the intravenous induction technique, 
yet the advantages of inhalational induction should be con-
sidered. Second, the desflurane requirement might be further 
reduced. Billard and colleagues noted that optimal balance 
was achieved at the MAC-awake concentration of desflurane 
when this was combined with intermediate concentrations of 
remifentanil, such as 5-7 ng/ml effect-site concentrations of 
remifentanil [24]. However, a response surface model of opioid-
volatile synergy suggested that at least a 1.3 vol% (0.7 MAC) of 
sevoflurane was required to assure a 95% possibility of hypnosis 
in the absence of adjuvant remifentanil [21]. Concerns about 
intraoperative awareness and postoperative recall made it 
crucial to maintain a 0.7 MAC of end-tidal desflurane because 
the combined remifentanil concentration might be lowered 
to 0 ng/ml during the up-and-down sequence. Finally, this 
study just aimed at finding a median effective concentration of 
remifentanil. Anesthetic practices frequently require the EC95 
values, yet the conventional up-and-down sequence failed 
to get such value because of the limited study design [29]. 
Furthermore, the efficacy and safety of the calculated EC95 value 
is not guaranteed because the value exceeded the tested range 
in the current study. A future study may be required to validate 
the EC95 value.
    In conclusion, this up-and-down study revealed that 3.7 ng/
ml was a median effective effect-site concentration of remi-
fentanil to suppress tachycardia and hypertension following 
laryngoscopic tracheal intubation when combined with 1 
MAC of desflurane. Hemodynamic stability and the absence 
of complication during anesthesia induction proved that 
this balanced technique was a feasible option for anesthesia 
induction with desflurane. We suggest a simple technique 
such as administering desflurane and remifentanil at fixed 
concentrations such as 1 MAC and 3.7 ng/ml, respectively, 
during the entire induction period.
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